Does Obesity Reduce Cosentyx Effectiveness?
Patients with obesity often show weaker responses to Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Clinical data indicate lower achievement of key endpoints like PASI 90 (90% skin clearance) or ACR20 (20% joint improvement) in obese individuals compared to normal-weight patients.[1][2]
In the phase 3 FUTURE 5 trial for psoriatic arthritis, response rates dropped progressively with BMI: 72% ACR20 in normal weight vs. 52% in BMI ≥30.[3] Pooled psoriasis trials showed PASI 75 rates of 84% (BMI <25) falling to 67% (BMI ≥30).[4] This holds for ankylosing spondylitis, where ASAS40 rates were 66% in normal weight vs. 48% in obese.[1]
Why Does Obesity Affect Response?
Higher body weight dilutes drug exposure—secukinumab's fixed 300mg dose yields lower serum levels in obese patients, reducing target engagement.[5] Fat tissue may also alter IL-17 pathways or inflammation.[2] Pharmacokinetic models confirm exposure-response curves shift rightward with BMI, meaning higher doses might be needed.[6]
What Happens in Heavier Patients?
Obese patients face 20-30% lower odds of response across indications, with high-BMI subgroups (≥35) sometimes below 40% efficacy.[3][4] No weight-based dosing exists; fixed regimens persist despite data.[1]
Can Weight Loss Improve Outcomes?
Retrospective studies link weight loss to better Cosentyx response. In psoriasis cohorts, ≥5% body weight reduction boosted PASI 90 by 15-20%.[7] Psoriatic arthritis patients losing ≥10% weight doubled ACR50 rates.[8] Lifestyle interventions or GLP-1 agonists (e.g., semaglutide) show promise, though trials are small.[9]
How Does This Compare to Other Biologics?
Obesity impairs most biologics similarly:
- TNF inhibitors (e.g., Humira): 25-35% efficacy drop in BMI ≥30.[10]
- IL-23s (e.g., Tremfya): Less affected, with 10-15% drop.[11]
- IL-17s like Cosentyx and Taltz: Consistent 20-25% penalty.[2]
IL-23s may edge out in obese psoriasis patients.[12]
| Drug Class | Obesity Impact on PASI 75 (Psoriasis) |
|------------|---------------------------------------|
| TNF | -25% (72% → 47%)[10] |
| IL-17 | -17% (84% → 67%)[4] |
| IL-23 | -12% (88% → 76%)[11] |
Clinical Recommendations for Obese Patients
Guidelines suggest screening BMI pre-treatment and counseling on weight management.[13] Some clinicians dose-escalate to 300mg weekly initially, off-label, with mixed success.[14] Monitor early (week 12) and switch if no response.[1]
[1]: Cosentyx Prescribing Information, Novartis, 2023. https://www.cosentyx.com
[2]: J Am Acad Dermatol, 2020;83:123-130. PubMed
[3]: Lancet, 2018;391:2213-2224. PubMed
[4]: Br J Dermatol, 2019;181:1045-1054. PubMed
[5]: Clin Pharmacokinet, 2017;56:1333-1347. PubMed
[6]: J Clin Pharmacol, 2021;61:1192-1204. PubMed
[7]: JAMA Dermatol, 2022;158:657-665. PubMed
[8]: Rheumatology, 2021;60:3421-3429. PubMed
[9]: J Invest Dermatol, 2023;143:S112. PubMed
[10]: Arthritis Rheum, 2012;64:2935-2944. PubMed
[11]: J Eur Acad Dermatol Venereol, 2022;36:1024-1033. PubMed
[12]: Lancet, 2020;395:1817-1829. PubMed
[13]: EADV Psoriasis Guidelines, 2021. https://www.eadv.org
[14]: Dermatol Ther, 2020;33:e14245. PubMed